Maurice Treacy's guest appearances

Maurice Treacy

The SharePickers Podcast with Justin Waite

Share Talk LTD

The ValueTheMarkets Podcast

Paul Haywood

Matt Lofgran

David Bramhill

Craig Brown

Paul Johnson

Matt Bull

Jack Oil

Gil Holzman

Mike Moles

Cathal Friel

James Campbell

Bob Smith

John Taylor

Michael Foster

Alan Simpson

OwlTail

Today’s guest on the ValueTheMarkets podcast is Maurice Treacy, Chief Commercial Officer of Open Orphan (LSE:ORPH) The company is focused on rare disease and orphan drug pharma services and aims to achieve rapid growth through the acquisition of smaller, high-margin pharma service providers. Following on from our earlier podcast with CEO, Cathal Friel, Maurice focusses on discussing the technical side of the business.  One of the key offerings the firm is developing is the first Genomic Health Database. Maurice gives further details and outlines the need for the database as well as highlighting the opportunity this presents to Open Orphan.  Author: Stuart Langelaan Disclosure:  The author was paid for this piece.  The author does not own shares in the company mentioned.  All opinions expressed are those of ValueTheMarkets and the respective guests unless otherwise stated and should not be construed as investment advice or a recommendation to buy shares in any featured Company. Listeners are advised to do their own extensive research before buying shares which, as with all small-cap exploration stocks, should be viewed as high risk. Investors should also seek the advice of a qualified investment adviser or stockbroker as they deem appropriate.

Today’s guest on the ValueTheMarkets podcast is Maurice Treacy, Chief Commercial Officer of Open Orphan (LSE:ORPH) The company is focused on rare disease and orphan drug pharma services and aims to achieve rapid growth through the acquisition of smaller, high-margin pharma service providers. Following on from our earlier podcast with CEO, Cathal Friel, Maurice focusses on discussing the technical side of the business. One of the key offerings the firm is developing is the first Genomic Health Database. Maurice gives further details and outlines the need for the database as well as highlighting the opportunity this presents to Open Orphan. Author: Stuart Langelaan Disclosure:  The author was paid for this piece.  The author does not own shares in the company mentioned. All opinions expressed are those of ValueTheMarkets and the respective guests unless otherwise stated and should not be construed as investment advice or a recommendation to buy shares in any featured Company. Listeners are advised to do their own extensive research before buying shares which, as with all small-cap exploration stocks, should be viewed as high risk. Investors should also seek the advice of a qualified investment adviser or stockbroker as they deem appropriate.

32: ValueTheMarkets Podcast 032 - with Maurice Treacy, Chief Commercial Officer of Open Orphan (ORPH)

Open Orphan signs agreement with Empiric Logic Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce it has signed a new strategic collaboration agreement ("the Collaboration") with Empiric Logic to build on the earlier work performed by Open Orphan and complete the build out of Open Orphan's Health Data platform, Europe's first rare disease, advocacy-led genomic database. Empiric Logic, a leading managed software service company which provides software to the Life Sciences, Pharma, Pharma Services and Biotech sectors, will incorporate its propriety, privacy preserving, and artificial intelligence enabled software into Open Orphan's Health Data platform to aid the collection and management capabilities of the software. The Collaboration is the final stage in the completion of Open Orphan's Genomic Health Data platform and will speed up its launch. The platform builds on the genomic analysis, database architecture know-how and prior professional experience between the founders of Empiric Logic and Maurice Treacy, Chief Commercial Officer at Open Orphan. Cathal Friel, Chief Executive of Open Orphan commented: "This is an exciting step towards the completion of our genomic Health Data platform, and we are delighted to have Empiric on board to help us quickly and securely become one of the largest databases of rare disease patients in Europe." Gareth O'Sullivan, CEO at Empiric Logic commented: "Empiric Logic is delighted to be supporting the Open Orphan team with the final steps of preparing the Genomic Health Data platform to accept first data. As part of the rollout of the Open Orphan database, it will be making substantial use of our artificial intelligence capabilities, such as for identification of rare-disease genetic mutations, but also for the potential identification of patients for clinical trials going forward."

Open Orphan signs agreement with Empiric Logic Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce it has signed a new strategic collaboration agreement ("the Collaboration") with Empiric Logic to build on the earlier work performed by Open Orphan and complete the build out of Open Orphan's Health Data platform, Europe's first rare disease, advocacy-led genomic database. Empiric Logic, a leading managed software service company which provides software to the Life Sciences, Pharma, Pharma Services and Biotech sectors, will incorporate its propriety, privacy preserving, and artificial intelligence enabled software into Open Orphan's Health Data platform to aid the collection and management capabilities of the software. The Collaboration is the final stage in the completion of Open Orphan's Genomic Health Data platform and will speed up its launch. The platform builds on the genomic analysis, database architecture know-how and prior professional experience between the founders of Empiric Logic and Maurice Treacy, Chief Commercial Officer at Open Orphan. Cathal Friel, Chief Executive of Open Orphan commented: "This is an exciting step towards the completion of our genomic Health Data platform, and we are delighted to have Empiric on board to help us quickly and securely become one of the largest databases of rare disease patients in Europe." Gareth O'Sullivan, CEO at Empiric Logic commented: "Empiric Logic is delighted to be supporting the Open Orphan team with the final steps of preparing the Genomic Health Data platform to accept first data. As part of the rollout of the Open Orphan database, it will be making substantial use of our artificial intelligence capabilities, such as for identification of rare-disease genetic mutations, but also for the potential identification of patients for clinical trials going forward."

Open Orphan PLC (LON:ORPH) Maurice Treacy, Chief Commercial Officer